Side effect of deferiprone as iron chelator in patient with thalassemia
Abstract: There are currently
three available iron chelators: deferoxamine (DFO), deferasirox (DFX) and
deferiprone (DFP). In Dr. Cipto Mangunkusumo Hospital and Indonesia, in
general, the accessibility of DFP for thalassemia patients has been adequate.
Even though its efficacy in removing iron has been proven by countless studies,
questions relating to its safety and possible side effects continue to be
raised.
Objective To assess common side effects of DFP usage by an intensive
literature search and compare them to that in a pediatric thalassemia patient,
in order to determine if the child’s symptoms in the were potentially caused by
DFP.
Methods A literature search using MeSH terms was done in PubMed. Full
copies of articles that fulfil the inclusion criteria, based on their title,
abstract, and subject descriptors, were critically appraised using The Joanna
Brigs Institute (JBI) critical appraisal tools.
Results A total of 10 research articles from 1998-2013 were deemed
applicable to this study including: 2 case reports, 5 prospective cohort
studies, 2 retrospective cohort studies, and 1 randomized control trial with a
grand total of 1,026 samples.
Conclusion Side effects of DFP include: neutropenia, agranulocytosis,
increased ALT, gastrointestinal problems, arthralgia or arthropathy, increased
appetite or weight, thrombocytopenia, urine discoloration, as well as auditory
and visual disturbances. Our case report patient’s symptoms of gum bleeding and
haemorrhagic mass are not related to her DFP consumption.
Keywords: thalassemia;
deferiprone; side effect
Author: Mikhael Yosia, Pustika
Amalia Wahidiyat
Journal Code: jpkedokterangg170180
